LIFEVANTAGE CORP Proceeds from Lines of Credit
LIFEVANTAGE CORP (LFVN) reported Proceeds from Lines of Credit of $2.50 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-27
- LIFEVANTAGE CORP proceeds from lines of credit for the quarter ending 2026-06-30 was $0.00.
- LIFEVANTAGE CORP proceeds from lines of credit for the quarter ending 2026-03-31 was $0.00.
- LIFEVANTAGE CORP proceeds from lines of credit for the quarter ending 2025-06-30 was $0.00.
- LIFEVANTAGE CORP proceeds from lines of credit for the quarter ending 2025-03-31 was $0.00.
- LIFEVANTAGE CORP proceeds from lines of credit for fiscal 2026 was $2.50M.
- LIFEVANTAGE CORP proceeds from lines of credit for fiscal 2025 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $0.00 derived: sum of 2 quarters · filed 2026-08-27 | $2.50M 10-K · filed 2026-08-27 | |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $2.50M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $2.50M 10-Q · filed 2026-02-04 | |||
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $0.00 derived: sum of 2 quarters · filed 2026-08-27 | $0.00 10-K · filed 2026-08-27 | |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $0.00 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $0.00 10-Q · filed 2026-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |